Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN)

Annals of Oncology : Official Journal of the European Society for Medical Oncology
V Launay-VacherB Sprangers

Abstract

A number of cancer therapy agents are cleared by the kidney and may affect renal function, including cytotoxic chemotherapy agents, molecular targeted therapies, analgesics, antibiotics, radiopharmaceuticals and radiation therapy, and bone-targeted therapies. Many of these agents can be nephrotoxic, including targeted cancer therapies. The incidence, severity, and pattern of renal toxicities may vary according to the respective target of the drug. Here, we review the renal effects associated with a selection of currenty approved targeted cancer therapies, directed to vascular endothelial growth factor or VEGF receptor(s) (VEGF/VEGFR), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor2 (HER2), BRAF, anaplastic lymphoma kinase (ALK), programmed cell death protein-1 or its ligand (PD-1/PDL-1), receptor activator of nuclear factor kappa-B ligand (RANKL), and mammalian target of rapamycin (mTOR). The early diagnosis and prompt treatment of these renal alterations are essential in the daily practice where molecular targeted therapies have a definitive role in the armamentarium used in many cancers.

References

Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael B AtkinsMatthew L Sherman
May 12, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric RaymondJean-Pierre Armand
Jun 24, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric K RowinskyJanice Dutcher
Dec 23, 2004·Endocrine-related Cancer·P M Harari
Mar 15, 2005·Clinical Pharmacokinetics·Vincent Launay-VacherGilbert Deray
Aug 18, 2005·Journal of the National Cancer Institute·Deborah SchragLeonard Saltz
Dec 21, 2006·Nature Clinical Practice. Cardiovascular Medicine·Paolo RaggiAntonio Bellasi
Jan 16, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Stuart M LichtmanMatti Aapro
Jul 20, 2007·Cancer·Vincent Launay-VacherUNKNOWN Renal Insufficiency and Cancer Medications (IRMA) Study Group
Aug 3, 2007·The Journal of Clinical Investigation·Shmuel Muallem, Orson W Moe
Jan 4, 2008·The New England Journal of Medicine·Michel AziziStéphane Oudard
Mar 14, 2008·The New England Journal of Medicine·Vera EreminaSusan E Quaggin
Sep 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Juliette ThariatGerard Milano
Feb 13, 2009·Oncology·Hassane IzzedineDavid Khayat
Apr 4, 2009·Anti-cancer Drugs·Vincent Launay-Vacher, Gilbert Deray
May 2, 2009·Journal of the American Society of Nephrology : JASN·Germaine WongJonathan C Craig
Oct 1, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Benjamin D Humphreys, Michael B Atkins
Dec 10, 2009·Folia Histochemica Et Cytobiologica·Katarzyna KlejnaMichał Myśliwiec
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerSuzanne L Topalian
Jul 3, 2010·Journal of the American Society of Nephrology : JASN·Henrik DimkeRené J Bindels
Nov 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alison T StopeckAda Braun
Nov 11, 2010·British Journal of Cancer·N JanusH Wildiers
Feb 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David H HenryHoward Yeh
Aug 30, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Bjarne OrskovSvend Strandgaard
Oct 26, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Samuel A WellsMartin J Schlumberger
Nov 3, 2011·JAMA : the Journal of the American Medical Association·Eric A EngelsMonica Lin
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Nov 28, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y KohS-H Lee

❮ Previous
Next ❯

Citations

Mar 5, 2016·European Journal of Pharmacology·George LiamisMoses S Elisaf
Sep 6, 2015·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Laura CosmaiMark A Perazella
Aug 4, 2016·The Veterinary Clinics of North America. Small Animal Practice·Murthy YerramilliMaha Yerramilli
Oct 27, 2016·Investigational New Drugs·Emilie BoissierBenoît Rousseau
Nov 14, 2018·Journal of the National Cancer Institute·Abhijat KitchluRon Wald
Feb 5, 2019·Current Oncology Reports·Harsh K Patel, Alok A Khorana
Nov 15, 2019·Critical Care Medicine·Cristina GutierrezStephen M Pastores
May 6, 2019·Nature Communications·Rhodora C CalizoEvren U Azeloglu
Oct 17, 2017·Oncotarget·Jolanta MałyszkoJacek Małyszko
Jul 13, 2016·Advances in Anatomic Pathology·Megan L TroxellNeeraja Kambham
Jan 1, 2017·Hämostaseologie·Minna Voigtlaender, Florian Langer
Dec 7, 2019·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Fatima TokhmafshanPaul R Goodyer
Jan 1, 2016·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Jolanta MalyszkoJacek Malyszko
Aug 3, 2016·Critical Care : the Official Journal of the Critical Care Forum·Norbert LameireDominique Benoit
Apr 23, 2017·Journal of Nephrology·Jordi BoverMario Cozzolino
Nov 28, 2018·Drugs & Aging·Zeina Al-MansourVenu Bathini
May 2, 2020·World Journal of Clinical Oncology·Maria Luísa Cordeiro SantosFabrício Freire de Melo
Nov 27, 2020·Journal of Nephrology·Laura CosmaiMaurizio Gallieni
Feb 15, 2017·Molecular Cancer Therapeutics·Antonella BorgattiDaniel A Vallera
Jan 6, 2021·Current Opinion in Supportive and Palliative Care·Jane CrimminNicolò Matteo Luca Battisti
Apr 22, 2021·The Journal of Obstetrics and Gynaecology Research·Yoshio Yoshida, Daisuke Inoue

❮ Previous
Next ❯

Related Concepts

Related Feeds

CZI Human Cell Atlas Seed Network

The aim of the Human Cell Atlas (HCA) is to build reference maps of all human cells in order to enhance our understanding of health and disease. The Seed Networks for the HCA project aims to bring together collaborators with different areas of expertise in order to facilitate the development of the HCA. Find the latest research from members of the HCA Seed Networks here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Related Papers

Clinical Advances in Hematology & Oncology : H&O
Gary R Hudes
Revue de pneumologie clinique
L GibaultH Blons
Advances in Pharmacology
Michael A Davies
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Michail IgnatiadisMartine Piccart
© 2022 Meta ULC. All rights reserved